Published in Bone Marrow Transplant on July 01, 1999
Frequent patient-to-patient transmission of hepatitis C virus in a haematology ward. Lancet (1995) 5.07
Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events. Lancet (1986) 2.38
Switch from Myc/Max to Mad1/Max binding and decrease in histone acetylation at the telomerase reverse transcriptase promoter during differentiation of HL60 cells. Proc Natl Acad Sci U S A (2001) 2.33
Splanchnic glucose and amino acid metabolism in obesity. J Clin Invest (1974) 1.73
Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut (2005) 1.70
Interleukin 6, tumour necrosis factor alpha, interleukin 1beta and interleukin 1 receptor antagonist promoter or coding gene polymorphisms in multiple myeloma. Br J Haematol (2000) 1.66
Immune deficiency in family members of patients with Hodgkin's disease. Cancer (1990) 1.61
Preoperative infusion of amino acids prevents postoperative hypothermia. Br J Anaesth (1996) 1.61
Telomerase reverse transcriptase promotes epithelial-mesenchymal transition and stem cell-like traits in cancer cells. Oncogene (2012) 1.55
Frequent amplification of the telomerase reverse transcriptase gene in human tumors. Cancer Res (2000) 1.52
Clinical significance of serum cytokine patterns during start of fever in patients with neutropenia. Br J Haematol (1995) 1.49
Clonal cell surface structures related to differentiation, activation and homing in B-cell chronic lymphocytic leukemia and monoclonal lymphocytosis of undetermined significance. Eur J Haematol (1989) 1.48
Hypocholesterolaemia in malignancy due to elevated low-density-lipoprotein-receptor activity in tumour cells: evidence from studies in patients with leukaemia. Lancet (1985) 1.46
Interleukin-10 mRNA expression in B-cell chronic lymphocytic leukaemia inversely correlates with progression of disease. Br J Haematol (1996) 1.45
Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells. Oncogene (2000) 1.41
Determinants of health-related quality of life in long-term survivors of Hodgkin's lymphoma. Qual Life Res (2004) 1.17
Lymphocyte abnormalities in untreated patients with Hodgkin's disease. Cancer (1976) 1.17
Augmented thermic effect of amino acids under general anaesthesia: a mechanism useful for prevention of anaesthesia-induced hypothermia. Clin Sci (Lond) (1994) 1.15
Interferon therapy in myelomatosis. Lancet (1979) 1.10
Real-time quantitative telomeric repeat amplification protocol assay for the detection of telomerase activity. Clin Chem (2001) 1.04
Suppression of telomerase reverse transcriptase (hTERT) expression in differentiated HL-60 cells: regulatory mechanisms. Br J Cancer (1999) 1.03
Natural killer cell activity in monoclonal gammopathies: relation to disease activity. Eur J Haematol (1990) 1.03
Blood T-lymphocyte functions in healthy adults in relation to age. Scand J Haematol (1982) 1.01
Effects remaining after withdrawal of long-term beta-receptor blockade. Reduced heart rate and altered haemodynamic response to acute propranolol administration. Br Heart J (1976) 1.01
Amplification of the c-myc oncogene in human plasma-cell leukemia. Int J Cancer (1985) 0.99
Persisting lymphocyte deficiences during remission in Hodgkin's disease. Clin Exp Immunol (1977) 0.99
Interleukin-10 gene promoter polymorphisms in multiple myeloma. Int J Cancer (2001) 0.98
Individual quality of life in long-term survivors of Hodgkin's lymphoma--a comparative study. Qual Life Res (2003) 0.98
D-verapamil and L-verapamil are equally effective in increasing vincristine accumulation in leukemic cells in vitro. Int J Cancer (1988) 0.97
Quality of life before and one year following stem cell transplantation using an individualized and a standardized instrument. Psychooncology (2008) 0.96
Early response to chemotherapy: a surrogate for final outcome of Hodgkin's disease patients that should influence initial treatment length and intensity? Ann Oncol (2002) 0.95
Multiple myeloma, Waldenström's macroglobulinemia, and benign monoclonal gammopathy: characteristics of the B cell clone, immunoregulatory cell populations and clinical implications. Adv Cancer Res (1984) 0.95
Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients. Br J Haematol (1996) 0.93
The incidence of cancer among blood donors. Int J Epidemiol (1990) 0.92
Risk profile and outcome in Hodgkin's lymphoma: is obesity beneficial? Ann Oncol (2005) 0.91
T cells in monoclonal gammopathies. Scand J Haematol (1982) 0.91
Lymphocyte abnormalities predicting a poor prognosis in Hodgkin's disease. A long-term follow-up. Cancer (1991) 0.90
Spontaneously DNA synthesizing blood and spleen lymphocytes in Hodgkin's disease. Scand J Haematol (1981) 0.90
Telomerase activity in plasma cell dyscrasias. Br J Cancer (2001) 0.90
Cyclin E overexpression in relapsed adult acute lymphoblastic leukemias of B-cell lineage. Blood (1996) 0.90
Inflammation and tissue repair markers distinguish the nodular sclerosis and mixed cellularity subtypes of classical Hodgkin's lymphoma. Br J Cancer (2009) 0.89
Monocyte function in Hodgkin's disease. Clin Exp Immunol (1982) 0.89
Studies on the preaortal paraganglia of newborn rabbits. Acta Physiol Scand Suppl (1966) 0.89
A prospective study on antibody response to repeated vaccinations with pneumococcal capsular polysaccharide in splenectomized individuals with special reference to Hodgkin's lymphoma. J Intern Med (2004) 0.89
Augmented thermic effect of amino acids under general anaesthesia occurs predominantly in extra-splanchnic tissues. Clin Sci (Lond) (1996) 0.89
Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Cancer Chemother Pharmacol (1993) 0.89
Immunological capacity of lymphocytes from untreated patients with Hodgkin's disease evaluated in mixed lymphocyte culture. Clin Exp Immunol (1975) 0.88
T-cell stimulation induced by idiotypes on monoclonal immunoglobulins in patients with monoclonal gammopathies. Scand J Immunol (1993) 0.87
Cytotoxic T-lymphocyte antigen-4 microsatellite polymorphism is associated with multiple myeloma. Br J Haematol (2001) 0.86
Type-specific anti-pneumococcal antibody subclass response to vaccination after splenectomy with special reference to lymphoma patients. Eur J Haematol (1989) 0.86
Flow cytometry and allele-specific oligonucleotide PCR are equally effective in detection of minimal residual disease in ALL. Leukemia (2001) 0.86
Longitudinal studies of blood lymphocyte capacity in Hodgkin's disease. Cancer (1981) 0.86
Antibody-dependent haemolytic activity of human leukaemic cells. Clin Exp Immunol (1980) 0.85
T-Lymphocyte deficiency following adult thymectomin man. Scand J Haematol (1975) 0.85
Post-traumatic stress symptoms in patients undergoing autologous stem cell transplantation. Acta Oncol (1999) 0.85
Successful pregnancy in a 28-year-old patient autografted for acute lymphoblastic leukemia following myeloablative treatment including total body irradiation. Bone Marrow Transplant (1993) 0.85
Post-splenectomy septicemia in Hodgkin's disease and other disorders. Acta Chir Scand (1980) 0.84
Epstein-Barr virus expression in Hodgkin's disease in relation to patient characteristics, serum factors and blood lymphocyte function. Br J Cancer (1999) 0.84
Chlorambucil/prednisone vs. CHOP in symptomatic low-grade non-Hodgkin's lymphomas: a randomized trial from the Lymphoma Group of Central Sweden. Ann Oncol (1994) 0.84
The effect of physical training on the sympathoadrenal response to exercise. Scand J Clin Lab Invest (1975) 0.84
Epstein-barr virus can infect B-chronic lymphocytic leukemia cells but it does not orchestrate the cell cycle regulatory proteins. J Hum Virol (2002) 0.84
Clinical findings and prognostic factors in chronic myeloid leukemias. Acta Med Scand (1986) 0.84
Intensive treatment in order to minimize the Ph-positive clone in CML. Danish-Swedish CML Group. Bone Marrow Transplant (1996) 0.84
Blood and lymph node T-lymphocyte subsets in non-Hodgkin lymphomas. Scand J Haematol (1983) 0.84
Myocardial rupture with cardiac tamponade as a lethal early manifestation of acute myeloblastic leukemia. Cancer (1982) 0.83
Differences in blood T and NK cell populations between chronic lymphocytic leukemia of B cell type (B-CLL) and monoclonal B-lymphocytosis of undetermined significance (B-MLUS). Leukemia (1989) 0.83
On the expression of cytosolic calcium-independent phospholipase A2 (88kDa) in immature and mature myeloid cells and its role in leukotriene synthesis in human granulocytes. FEBS Lett (1998) 0.83
Circulatory effects of isometric muscle contractions, performed separately and in combination with dynamic exercise. Eur J Appl Physiol Occup Physiol (1976) 0.83
Immunological and hematological abnormalities in chronic alcoholism. Acta Med Scand (1980) 0.83
Osmiophilic granules in preaortal paraganglia from newborn rabbits. Acta Physiol Scand (1965) 0.83
Prognostic factors in Hodgkin's disease with special reference to age. Cancer (1984) 0.83
Validation of an extended version of the SEIQoL-DW in a cohort of Hodgkin lymphoma' survivors. Qual Life Res (2005) 0.83
Immunodeficiency and prognosis in Hodgkin's disease. Acta Med Scand (1975) 0.82
Prognostic factors in Hodgkin's disease. II. Role of the lymphocyte defect. Scand J Haematol (1978) 0.82
Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications. Haematologica (2000) 0.82
Immunological defects in healthy twin siblings to patients with Hodgkin's disease. Scand J Haematol (1977) 0.82
Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia. Med Oncol (2002) 0.82
Prostaglandin-mediated inhibition of noradrenaline release: IV. Prostaglandin synthesis is stimulated by myocardial adrenoceptors differing from the alpha- and beta-type. Acta Physiol Scand (1978) 0.82
Do steroids increase lymphoma risk? A case-control study of lymphoma risk in polymyalgia rheumatica/giant cell arteritis. Ann Rheum Dis (2005) 0.81
Telomerase reverse transcriptase inhibition stimulates cyclooxygenase 2 expression in cancer cells and synergizes with celecoxib to exert anti-cancer effects. Br J Cancer (2013) 0.81
Reactivation of chronic hepatitis C after withdrawal of immunosuppressive therapy. J Intern Med (1993) 0.81
Therapeutic effects of low-dose cytosine arabinoside, alpha-interferon, 1 alpha-hydroxyvitamin D3 and retinoic acid in acute leukemia and myelodysplastic syndromes. Eur J Haematol (1988) 0.81
Intermittent high-dose melphalan/prednisone vs continuous low-dose melphalan treatment in multiple myeloma. Eur J Cancer Clin Oncol (1983) 0.81
RT-PCR analysis of the MOZ-CBP and CBP-MOZ chimeric transcripts in acute myeloid leukemias with t(8;16)(p11;p13). Genes Chromosomes Cancer (2000) 0.81
Biological markers may add to prediction of outcome achieved by the International Prognostic Score in Hodgkin's disease. Ann Oncol (2000) 0.81
LMP-1, the Epstein-Barr virus-encoded oncogene with a B cell activating mechanism similar to CD40. Immunol Lett (1999) 0.81
Effect of verapamil on daunorubicin accumulation in human leukemic cells with different levels of MDR1 gene expression. Leuk Res (1993) 0.81
Oral etoposide in patients with hematological malignancies: a clinical and pharmacokinetic study. Med Oncol (2001) 0.81
Quantitative determination of mdr1 gene expression in leukaemic cells from patients with acute leukaemia. Br J Cancer (1992) 0.81
Immunosuppressive serum factors and lymphocyte deficiency in Hodgkin's disease. J Clin Lab Immunol (1979) 0.80
Endotoxemia in febrile patients with hematological malignancies. Relationship of type of bacteremia, clinical findings and serum cytokine pattern. Infection (1997) 0.80
Epidemiological study of Hodgkin's disease in Cuba and Sweden. Oncology (1990) 0.80
Renal extraction of insulin and C-peptide in man before and after a glucose meal. Clin Physiol (2001) 0.80
No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease. Leukemia (2003) 0.80
Prognostic effect of early diagnostic splenectomy in Hodgkin's disease: a randomized trial. Br J Cancer (1980) 0.80
Tissue eosinophilia in relation to immunopathological and clinical characteristics in Hodgkin's disease. Leuk Lymphoma (2001) 0.80